![Teva Canada Announces the Launch of (Pr)Teva-Tolterodine Tablets and (Pr) Teva-Tolterodine LA Extended Release Capsules, Generics of (Pr)Detrol® and (Pr)Detrol LA® Teva Canada Announces the Launch of (Pr)Teva-Tolterodine Tablets and (Pr) Teva-Tolterodine LA Extended Release Capsules, Generics of (Pr)Detrol® and (Pr)Detrol LA®](http://photos.newswire.ca/images/20151215_C6454_PHOTO_EN_564829.jpg)
Teva Canada Announces the Launch of (Pr)Teva-Tolterodine Tablets and (Pr) Teva-Tolterodine LA Extended Release Capsules, Generics of (Pr)Detrol® and (Pr)Detrol LA®
![Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder](https://mms.businesswire.com/media/20200921005170/en/819864/4/Interactive_Media_Placeholder_webready.jpg)
Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder
![Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace](https://mms.businesswire.com/media/20180914005613/en/678526/4/AJOVY+Image.jpg)
Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace
![Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal](https://media.bizj.us/view/img/10777492/47002105ovaleap300ie-0-5ml*750xx640-360-0-60.jpg)
Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal
![Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter | FDA Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter | FDA](https://www.fda.gov/files/styles/recall_image_small/public/image-1_53.png?itok=-VZ3-Pnq)